Market News & Trends
Transdermal Specialties Announces Success of Insulin Patch Clinical Trial
In June, 2015 TSI began the HPT-6B.3 clinical trial with 12 type-2 diabetic volunteers, both male and female subjects, who were subject to a 24…
Ludwig Cancer Research & University of Oxford Launch Cancer Immunotherapy Spinout
Isis Innovation, the University of Oxford’s technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, iOx…
Exostar's Identity Hubs - Making Security a Business Enabler Throughout the Drug Development Process
With a price tag north of $1B and a duration in the neighborhood of a decade, the drug development process costs too much and takes…
Avexxin Completes Phase I/IIA Study; Achieves PoC In Man With Topical Formulation
Avexxin's lead compound AVX001 in a topical formulation has shown Proof-of-Concept in man in an ascending dose Phase I/IIa study encompassing 26 patients suffering from…
ImmunoCellular Therapeutics Establishes Agreement With Novella Clinical
ImmunoCellular Therapeutics, Ltd. recently announced the establishment of an agreement with Novella Clinical to conduct the Phase III registration trial of ICT-107 in patients with…
Rock Creek Pharmaceuticals Reports Human Proof-of-Principle Study
Rock Creek Pharmaceuticals, Inc., recently announced the results of a human proof-of- principle study with anatabine citrate, the company's lead compound. Results from the study…
AAA Signs Distribution Agreement With FUJIFILM RI Pharma
Advanced Accelerator Applications S.A. (AAA) recently announced it has entered into a distribution agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD (FRI).…
Palatin Technologies Completes $30-Million Financing
Palatin Technologies, Inc. recently announced it has closed on a private placement of Series E warrants to purchase 21,917,808 shares of its common stock and…
Capsugel Unveils New Facility; Significantly Expands Capability
Capsugel recently announced it has completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site in Bend, OR. The completion…
“Biomaterial of the Future” Nanocellulose to Send Market Booming with 42.8% CAGR
Nanocellulose (NC) is quickly becoming commercially available worldwide, and the production capacity is increasing exponentially. BCC Research reveals in its new report, Cellulose Nanoparticles: Processing,…
Exostar & Taigle Partnership Delivers Solutions to Life Science & Healthcare Markets
Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Taigle mySignatureBook, a leading digital workflow provider in the…
Global Biosimilars Market Value Could Hit $55 Billion
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth…
PharmaCyte Biotech Enters Into Research & Consulting Agreement
PharmaCyte Biotech, Inc. recently announced it has signed a major Research Services Agreement and an important Consulting Contract with the University of Technology Sydney (UTS)…
Protein Sciences Reports Topline Data for Flublok Quadrivalent
Protein Sciences Corporation recently announced topline data showing that Flublok Quadrivalent, the quadrivalent version of FDA-approved trivalent Flublok influenza vaccine, outperformed a traditional influenza vaccine…
Vaxon Biotech Granted Patent for New Cancer Vaccine Candidates
Vaxon Biotech recently announced it has been granted a new patent in Japan. This patent (JP application n°2012-502822) covers a series of optimized cryptic peptides…
Perle Bioscience’s Insulin Independence Revolutionary Phase III Trial
Perle Bioscience, Inc. recently announced enrollment for the Insulin Independence Trial (IIT). This trial is the first and only Phase III trial to test a…
Cristal Therapeutics Highlights Proprietary CriPec Nanomedicine Platform & Promising Data
Cristal Therapeutics recently announced the publication of three articles on CriPec-based nanomedicines in Nano Today, Journal of Controlled Release, and Biomaterials. The publications are co-authored…
Vaccinex Announces Initiation of Phase III Clinical Trial for Huntington's Disease
Vaccinex, Inc. recently announced it has initiated a Phase II clinical trial to assess the safety, tolerability, and efficacy of anti-semaphorin 4D antibody VX15/2503 (VX15)…
Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined…
Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies…
